Epigenetic Regulation of Endothelial Cell Function by Nucleic Acid Methylation in Cardiac Homeostasis and Disease

被引:0
作者
Adam Russell-Hallinan
Chris J. Watson
Denis O’Dwyer
David J. Grieve
Karla M. O’Neill
机构
[1] Queen’s University Belfast,Wellcome
来源
Cardiovascular Drugs and Therapy | 2021年 / 35卷
关键词
Epigenetics; Endothelial cells; DNA methylation; RNA methylation; Heart failure;
D O I
暂无
中图分类号
学科分类号
摘要
Pathological remodelling of the myocardium, including inflammation, fibrosis and hypertrophy, in response to acute or chronic injury is central in the development and progression of heart failure (HF). While both resident and infiltrating cardiac cells are implicated in these pathophysiological processes, recent evidence has suggested that endothelial cells (ECs) may be the principal cell type responsible for orchestrating pathological changes in the failing heart. Epigenetic modification of nucleic acids, including DNA, and more recently RNA, by methylation is essential for physiological development due to their critical regulation of cellular gene expression. As accumulating evidence has highlighted altered patterns of DNA and RNA methylation in HF at both the global and individual gene levels, much effort has been directed towards defining the precise role of such cell-specific epigenetic changes in the context of HF. Considering the increasingly apparent crucial role that ECs play in cardiac homeostasis and disease, this article will specifically focus on nucleic acid methylation (both DNA and RNA) in the failing heart, emphasising the key influence of these epigenetic mechanisms in governing EC function. This review summarises current understanding of DNA and RNA methylation alterations in HF, along with their specific role in regulating EC function in response to stress (e.g. hyperglycaemia, hypoxia). Improved appreciation of this important research area will aid in further implicating dysfunctional ECs in HF pathogenesis, whilst informing development of EC-targeted strategies and advancing potential translation of epigenetic-based therapies for specific targeting of pathological cardiac remodelling in HF.
引用
收藏
页码:1025 / 1044
页数:19
相关论文
共 936 条
[1]  
Kelder JC(2011)The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure Circulation 124 2865-2873
[2]  
Cramer MJ(2016)2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC Eur Heart J 37 2129-2200
[3]  
van Wijngaarden J(2015)A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010 JAMA Intern Med 175 996-1004
[4]  
van Tooren R(2009)Improving survival in the 6 months after diagnosis of heart failure in the past decade: population-based data from the UK Heart 95 1851-1856
[5]  
Mosterd A(2000)Left ventricular remodeling after myocardial infarction: pathophysiology and therapy Circulation 101 2981-2988
[6]  
Moons KG(2015)Extracellular matrix communication and turnover in cardiac physiology and pathology Comprehensive Physiology 5 687-719
[7]  
Ponikowski P(2013)Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes Circ Res 113 603-616
[8]  
Voors AA(2016)Epigenetic therapy for the treatment of hypertension-induced cardiac hypertrophy and fibrosis J Cardiovasc Pharmacol Ther 21 127-137
[9]  
Anker SD(2018)Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats J Mol Cell Cardiol 120 53-63
[10]  
Bueno H(2013)BET acetyl-lysine binding proteins control pathological cardiac hypertrophy J Mol Cell Cardiol 63 175-179